News

Efficacy signals have been observed in Starpharma’s clinical trials of dendrimer enhanced product (DEP) cabazitaxel and docetaxel

29 August 2019 Starpharma said both DEP-cabazitaxel and DEP-docetaxel had been showing “promising interim results”, with several patients dosed with DEP-cabazitaxel showing efficacy signals in tumors including prostate, ovarian and pancreatic cancer. In January 2018, Starpharma said it…

Bluechiip revenue for FY19 up 82.5%

29 August 2019 Bluechiip says revenue for the year to June 30, 2019 was up 82.5 percent to a record $1,025,052 with net loss after tax up 30.7 percent to $3,257,996. Bluechiip said revenue was from sales of…

Noxopharm’s NOX66 reduces tumor size and pain in patient study for prostate cancer

29 August 2019 Noxopharm says interim three-month results of its 11-patient study of Veyonda or NOX66 with radiotherapy for prostate cancer has reduced tumor size and pain. Noxopharm said it administered a single, 15-day course of 1,200mg of…

Expressions Of Interest for BioMelbourne Network – Board Director Vacancies

29 August 2019 (EOI close – 16 September) BioMelbourne Network has for the past 18 years championed an environment that has enabled Melbourne organisations to innovate, commercialise and to impact the future of healthcare locally and globally.   BioMelbourne…

Collaborative Research Agreement between VivaZome Pty Ltd and ToolGen, Inc.

27 August 2019 Melbourne, Australia and Seoul, South Korea: VivaZome Therapeutics Pty Ltd (“VivaZome”) and ToolGen, Inc (“ToolGen”) have announced the execution of a collaborative research and option agreement to explore gene-editing of cells for enhanced exosome production.…

Nucleus Network expansion creates first global, multi-site early phase trial organisation with investment in USA-based phase I clinical trials organization, Prism Clinical Research.

27 August, 2019 Nucleus Network, Australia’s leading early-phase clinical research organization, is pleased to announce it has acquired a majority shareholding in Prism Clinical Research, a 52-bed, early-phase clinical research facility located in Minneapolis/St. Paul, Minnesota, USA. The…

NOX receives 2018/19 Federal Government R&D tax rebate

23 August 2019 Sydney, Australia. Noxopharm Limited (ASX: NOX) is pleased to announce that it has received $3.71M cash rebate as part of the Federal Government R&D Tax Incentive Scheme. Greg van Wyk, Noxopharm Chief Executive Officer, said,…

Applications open for Victorian Government Women’s Board Leadership Program

26 August 2019 Nominations close: Tuesday 10 September 2019 What is the Women’s Board Leadership Program? The Women’s Board Leadership Program encourages women to serve, stay, and excel on community and government boards. The program offers a range of governance…

PLEXOVAL exosome wound healing human study starts – Exopharm Limited

26 August 2019 Melbourne, Australia: Regenerative medicine company Exopharm Limited (ASX:EX1) announces the start of the PLEXOVAL Phase 1 study, the first human clinical trial using exosomes for wound healing. This is an important step forward as a…

Research Australia welcome Australian Academic and Researcher to its Board of Directors

22 August 2019 Research Australia has welcomed to its Board, Professor Melissa Little, Theme Director of Cell Biology at the Murdoch Children’s Research Institute, Program Leader of Stem Cells Australia, Professor, Department of Pediatrics, and Honorary Professor, Anatomy…

Largest ever study finds links in epilepsy genes – Melbourne University & Austin Health

2 August 2019 Researchers and patients from Austin Health and the University of Melbourne have been involved in the largest ever study looking at the genetic sequences of people with epilepsy. The international research, published this week in…

Lab-on-a-chip drives search for new drugs to prevent blood clots – RMIT University

20 August 2019 A tiny lab the size of a postage stamp could be the next big thing in the search for safer anti-clotting drugs to prevent heart attacks and strokes. The effectiveness of current anti-clotting medication can…

Home

News & opinion

Member Directory

Events